Are we ready to use surrogate end points and surrogate tissues to evaluate response to chemopreventive and therapeutic intervention?
Lotan
R
R
D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology; D015415:Biomarkers; D001706:Biopsy; D002986:Clinical Trials as Topic; D006302:Health Services Research; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D009055:Mouth / Q000473:pathology; D009092:Mucous Membrane / Q000473:pathology; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology* / Q000517:prevention & control; D016896:Treatment Outcome; D014212:Tretinoin / Q000378:metabolism
D018931:Antineoplastic Agents, Hormonal; D015415:Biomarkers; D007093:Imidazoles; D014212:Tretinoin; C061121:liarozole